Official Program

This is the official program! Check out our amazing speakers. 

Thursday March 9

7:30 - 8:30

Registration – Exhibition Hall
Breakfast – Montreal Room

8:30 - 8:40

Welcome from CellCAN – Regenerative Medicine and Cell Therapy Network

Denis Claude Roy, CEO, CellCAN

Fortifications Room 

8:40 - 9:00

Learning from the patients’ perspectives


Michel Rochon, Scientific journalist
Denis Claude Roy, CEO of CellCAN


Jennifer Molson, Survivor of multiple sclerosis symptoms
William Brock, Survivor of leukemia

Fortifications Room

Theme 1: Opportunities and challenges of recent innovations in cell and gene therapy


Michel Rochon, Scientific journalist
Denis Claude Roy
, CEO, CellCAN

Fortifications Room

 9:00 - 10:00

Innovation in cancer therapy : CAR-T, game changer in cancer treatment?

Overview of the CAR-T revolution
Jerome Ritz, Executive Director, Connell O'Reilly Cell Manipulation at the Dana Farber Cancer Institute

The TAC receptor: Taking a new CAR for a spin
Jonathan Bramson, Director, Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing

10:00 - 10:30

Health break and exhibitors visit


Innovation in viral and gene Therapies

Oncolytic virus to promote anticancer activity
John Bell
, Senior Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute

CRISPR/Cas9 may be used to treat hereditary diseases
Jacques Tremblay
, Professor in the Department of Molecular Medicine, Laval University

11:30 -13:00

Lunch, networking and exhibitors visit

Montreal Room

Theme 2: Preparing Canada for the cell and gene revolution


Michel Rochon, Scientific journalist
James Price, President and CEO, Canadian Stem Cell Foundation

Fortifications Room

13:00 - 13:40

Dr. Janet Rossant presents the Council of Canadian Academies (CCA) latest workshop report on the opportunities and challenges for regenerative medicine in Canada

Dr Janet Rossant, President & Scientific Director of the Gairdner Foundation and Chair of the steering committee of the CCA workshop on regenerative medicine

13:40 - 14:10

Key enablers and barriers for cell and gene therapy translation in Canada

Joanne Castonguay, Research Director, Institute for Research on Public Policy (IRPP)

14:10 - 15:10

Panel - Advancing cell therapy through national strategies and initiatives: international examples

The California experience (CIRM)
Geoffrey Lomax
, Senior Officer, CIRM Strategic Infrastructure

How Britain makes it work (Catapult)
Dominic Bowers
, Head of Clinical Operations & Development, Catapult

Fast-tracking strategies in Japan (Jetro)
Tyson Garbe
, Assistant Director, Trade and Investment, JETRO Toronto

15:10 - 15:30

Health break and exhibitors visit

15:30 - 16:30

Parallel workshops: Addressing key elements to engage in the cell and gene therapy revolution

Saint-Antoine Room Ville-Marie A Room  Ville-Marie B Room

Strategically planning for manufacturing changes between early and late clinical trials

Moderator: Patrick Bedford, Manager, Clinical Translation & Regulatory Affairs, CCRM

Nadine Kolas, Senior Policy Analyst, Health Canada

Sowmya Viswanathan, Lead, CellCAN Manufacturing Platform, Assistant Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto, Affiliate Scientist, Krembil Research Institute, University Health Network

Quality gaps in funding requests for translational projects

Phil Welford, Executive Director, Stem Cell Network

Ethics and “Cellular Genomics”?

Bartha Knoppers, Director of the Centre of Genomics and Policy at the Faculty of Medicine, McGill University

16:30 - 16:45

Report on parallel workshop and wrap-up of the day
Wrap-up of the day

Fortifications Room

16:45 - 17:00

Denis Claude Roy is proud to introduce…

ISCT ANNOUNCEMENT, Queenie Jang, Executive Director, International Society for Cell Therapy

Denis Coderre, Montreal Mayor

17:00 - 18:30

Cocktail - Sponsored by C3i

Exhibition Hall

Friday March 10

7:30 - 8:30

Registration – Exhibition Hall 
Breakfast – Montreal Room 

8:30 - 8:35

Introduction to day 2 activities

Michel Rochon, Scientific journalist

Fortifications Room

Theme 3:  Manufacturing - what we have learned and what the future holds


Michel Rochon, Scientific journalist
Armand Keating
, Director, Cell Therapy Program, University Health Network

Fortifications Room

8:35 - 9:35

Manufacturing : Foundation of the cell and gene therapy revolution

Manufacturing of CAR-Ts
Isabelle Rivière
, Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center

Clarifying the meaning of GMP, GLP, QA, QC, etc.
Adrian Gee
, Director, Clinical Applications Lab, Baylor College of Medicine

9:35 - 10:35 

Panel - Manufacturing to deliver novel therapies to patients

Manufacturing in an academic setting
Jerome Ritz
, Executive Director, Connell O’Reilly Cell Manipulation, Dana Farber Cancer Institute

Translating academia to industry
Philippe Hénon
, President and Scientific Director, CellProthera

10:35 - 11:00

Health break and exhibitors visit

11:00- 11:50

Parallel workshops: Reflection on cell and gene manufacturing enhancing approaches

Saint-Antoine Room Ville-Marie A Room Ville-Marie B Room

Sharing vision for manufacturing autologous CAR-T cells

Paul Bowles
, Development Scientist, GE Cell Therapy Technologies

Raelyn Rosa
, MASc Design Engineer, Octane Biotech

Innovation to address unmet needs

James Piret, University of British Columbia Professor & CellCAN Bioengineering Leader

CRISPR – From bacteria to cell therapy

David Guay, Research director, Feldan Therapeutics

11:50 - 12:10 Report on parallel workshop

12:10 - 13:30

Lunch, networking and exhibitors visit

Theme 4:  Making Canada a central hub for commercializing cell and gene therapy


Michel Rochon, Scientific journalist
Lambert Busque
, Chief Medical Officer, Center for Commercialization of Cancer Immunotherapies (C3i)

Fortifications Room

13:30 - 14:30

Successful cell and gene therapy business models

Getting a start-up going
Jonathan Bramson
, Director, Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing

Building a business case for venture capitals
Michael May
, CEO, Centre for Commercialization of Regenerative Medicine (CCRM)

Centre for Commercialization of Cancer Immunotherapy (C3i) business model
Lambert Busque
, Chief Medical Officer, C3i

14:30 - 15:00

Making cell and gene therapy happen in Canada...who will pay and how much

Cost effectiveness analysis
Tania Bubela
, Professor, School of Public Health, Alberta University

15:00 - 15:30

Health break and exhibitors visit

15:30 - 16:00

Panel on reimbursement issues of cell and gene therapy

Canadian perspective on reimbursement
Maureen Trudeau
, Chair for the Expert Review Committee of the Pan Canadian Oncology Drug Review (pCODR)

Integration of innovation in Quebec: INESSS perspective
Michèle de Guise
, Director, Direction des services de santé et de l’évaluation des technologies, Institut national d’excellence en santé et en services sociaux (INESSS)

Fortifications Room

16:00 - 16:30

Vision for Canada from the key structuring networks

Closing remarks and next steps

Denis Claude Roy, CEO, CellCAN